JHVEPhoto/iStock Editorial via Getty Images Argus has upgraded Teva (NYSE:TEVA) to buy, citing valuation and the approval of several new products. “After several years of challenges, Teva appears to have steadied its ship, launching a range of new drugs and achieving margin growth across all of its three primary businessContinue Reading
Analysts at Argus Research have raised their full-year profit forecast for Netflix (NASDAQ:NFLX) after being encouraged by the company’s move into live sports programming with the NFL game streaming deal and for trying out new experiential initiatives to retain and/or grow its customer base. Argus has raised its 2024 EPSContinue Reading
kodda/iStock via Getty Images Targa Resources (NYSE:TRGP) -1.5% in Wednesday’s trading after posting a nearly 10-year high early in the session, as Argus launched coverage with a Buy rating and $140 price target, citing the company’s strong project backlog and plans to buy back shares. Argus analyst John Staszak expectsContinue Reading
Volume away from semiconductor ETFs’ (SMH), (SEMI), (NASDAQ:SOXX) overbought conditions could mean some long-term bullishness with other parts of the market seeing gains, according to an Argus Research Market Movers note. Analyst Mark Arbeter wrote that funds have rotated away from the semis (SMH), (SEMI), (SOXX) and into other partsContinue Reading
